Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies (Related Reports)

Triple Analysis: Angiogenesis, Cancer Vaccines and Antibodies


March 19, 2013
5072 Pages - SKU: BIOS5014693
License type:
PDF E-mail From Publisher      US $5,175.00
Global Site License Fulfilled by Publisher      US $12,937.50
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014
3/12/2014 | published by: La Merie Publishing
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies 2014 Biosimilar and Biosuperior Therapeutic Antibodies 2014 The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodies 2014 provides a competitor evaluation in  |  read more...
$1,523.00
Analytical Tool - Apoptosis in Oncology
3/25/2014 | published by: BioSeeker Group AB
Analytical Tool - Apoptosis in Oncology Analytical Tool - Apoptosis in Oncology" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of  |  read more...
$11,625.00
Analytical Tool - Antibodies and Peptides in Oncology
3/25/2014 | published by: BioSeeker Group AB
Analytical Tool - Antibodies and Peptides in Oncology Analytical Tool – Antibodies and Peptides in Oncology offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development  |  read more...
$22,312.50
Cancer Vaccines Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
Cancer Vaccines Drug Pipeline Update 2014 Cancer vaccines offer an attractive therapeutic addition, delivering treatment of high specificity, low toxicity and prolonged activity. However, despite years of R&D, a reproducible survival benefit has proved elusive, leaving  |  read more...
$5,622.50
Investigation Report on China Adalimumab Market, 2010-2018
3/6/2014 | published by: China Research and Intelligence Co., Ltd.
Investigation Report on China Adalimumab Market, 2010-2018 Adalimumab is a TNF (tumor necrosis factor) inhibiting anti-inflammatory drug, the first fully human monoclonal antibody drug approved by the FDA. It was discovered through collaboration between BASF Bioresearch  |  read more...
$1,800.00
Competitor Analysis: Cancer Vaccines
3/24/2014 | published by: La Merie Publishing
Cancer Vaccines The present Competitive Intelligence report about Cancer Vaccines provides a competitor evaluation in the field of novel prophylactic and therapeutic vaccines to fight cancer as of March 2014. Purchase of  |  read more...
$1,112.00
Analytical Tool - Cancer Immunotherapy
3/25/2014 | published by: BioSeeker Group AB
Analytical Tool - Cancer Immunotherapy Analytical Tool- Cancer Immunotherapy offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in immunotherapy drug development for the treatment of cancer. It is at  |  read more...
$20,437.50
Analytical Tool - Cancer Therapeutic Antibodies
3/25/2014 | published by: BioSeeker Group AB
Analytical Tool - Cancer Therapeutic Antibodies Analytical Tool - Cancer Therapeutic Antibodies offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer.  |  read more...
$14,810.00
Analytical Tool - Cancer Vaccines
3/25/2014 | published by: BioSeeker Group AB
Analytical Tool - Cancer Vaccines Analytical Tool - Cancer Vaccines offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer vaccine drug development. It is at the same time  |  read more...
$11,625.00
Antibodies in Oncology Drug Pipeline Update 2014
3/25/2014 | published by: BioSeeker Group AB
Antibodies in Oncology Drug Pipeline Update 2014 The commercial and therapeutic success of antibodies like Rituxan, Avastin, and Erbitux will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the  |  read more...
$5,622.50